Human epidermal growth factor receptor type 2 (HER2) is a type of transmembrane tyrosine kinase receptor that normally regulates cell growth and survival, as well as adhesion, migration, differentiation, and other cellular responses. It is overexpressed in 20%-30% of invasive breast carcinomas. HER2 positivity conveys a poor prognosis and decreased overall survival as well as an altered response to anthracycline (AC) chemotherapeutic regimens. Trastuzumab (TZB) (Herceptin; Genentech, Inc) is a recombinant humanized monoclonal antibody that binds to the extracellular domain of the HER2 receptor. Use of TZB in HER2-positive breast cancer became the greatest breakthrough therapy which reduces mortality and dramatically improves disease-free survival. Pooled results from 5 randomized trials of adjuvant TZB showed a significant reduction of mortality (P b .00001), recurrence (P b .00001), metastases rates (P b .00001), and second tumors other than breast cancer (P = .007) as compared with no-adjuvant-TZB patients. 1 In 2001, Slamon et al 2 reported 8.8% to 11% incidence of cardiotoxicity in patients receiving paclitaxel and TZB compared with 1% to 4% in those who received paclitaxel alone, and 26% to 28% in those on TZB and ACs vs 6% to 9.6% on AC alone. Multiple studies have been done since and have shown similar results. [3] [4] [5] Most of the cases of TZB-induced cardiomyopathy are reversible; however, once TZB is discontinued, oncologists are frequently hesitant to reexpose patients to this agent. Cardiotoxicity results in discontinuation of TZB in up to 19% of patients 3 . In our retrospective study, 19.5% of patients permanently or temporarily discontinued TZB secondary to cardiomyopathy. 6 There are some reports, primarily from single-center studies, demonstrating the protective effects of angiotensin-converting enzyme (ACE) inhibitors and β-blockers (BBs) in chemotherapy-induced cardiotoxicity. Specifically, Cardinale et al 7 reported a 100% prevention of AC-induced cardiomyopathy by enalapril, an ACE inhibitor. Similarly, Kalay et al 8 described a highly successful use of carvedilol, a BB, for prevention of chemotherapy-associated cardiac toxicity. Based on these reports, as well as on our preliminary data, 6 we hypothesized that patients randomized to receive an ACE inhibitor or a BB, simultaneously with initiation of TZB for HER2-positive breast cancer, would preserve better cardiac function than those randomized to placebo. We defined cardiotoxicity as decrease in left ventricular ejection fraction (LVEF) of b50% with a 5% drop from baseline, or a N 10% decrease in ejection fraction after initiating TZB.
Methods
We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial evaluating the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release [ER]) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy. The primary objective of this study is to determine if administration of lisinopril or carvedilol phosphate-ER, compared with placebo, will reduce the incidence of TZB-induced cardiotoxicity, as measured by LVEF, in patients receiving adjuvant or neoadjuvant therapy for HER2-positive breast cancer. The secondary objectives of this study are to determine whether participants on active agent have fewer interruptions in TZB therapy due to cardiomyopathy, determine if treatment effects are consistent in AC and non-AC cohorts, evaluate changes in quality of life (QOL) among the treatment groups during the study intervention, evaluate the long-term effects of the prevention of cardiomyopathy and impact on HRQL for either or both active agents, and compare the predictive value of troponin I (TnI) and B-type natriuretic peptide (BNP) in the identification of TZB cardiotoxicity.
We chose the extended-release Coreg XR rather than generic carvedilol, because, like lisinopril, it is taken only once daily and carvedilol has to be taken twice a day. A double-blind design of the study mandated a matching pattern of use of all the drugs in the trial.
The trial is registered as SCUSF 0806 (SunCoast University of South Florida) and has a ClinicalTrials.gov Identifier NCT01009918. The study described was supported by award number U10CA081920 from the National Cancer Institute. Because the trial was designed as a "real-life" study, we allowed the participating centers to select their preferred imaging modality. The LVEF is being evaluated by echocardiography or multigated acquisition scan, depending on the preferences of the clinical investigators. To provide consistency within centers, we required utilization of similar imaging modality throughout the follow-up, that is, if the patient had an echocardiogram at the baseline, subsequent images were also obtained by echocardiography. Because we realize that multitude of the sites may provide inconsistent readings, the Echo substudy was designed, where the analysis of sample echocardiograms is being done by Duke core echocardiographic laboratory. Specifically, echocardiograms of all patients meeting the definition of cardiotoxicity per their local sites, as well as their age-matched controls without cardiotoxicity by local readers, were sent to the core laboratory. The results will be reported separately from the main trial.
Definition of TZB-induced cardiotoxicity
TZB-induced cardiotoxicity usually manifests in decrease of LVEF. There is no uniform definition of TZB-induced cardiotoxicity. When our trial was being designed, the literature demonstrated high heterogeneity in the definitions. 9 Examples are shown in Table. For the SCUSF 0806 trial, we chose the definition of cardiotoxicity similar to Piccart-Gebhart et al 10 :
1. A decrease in LVEF of ≥10% in patients whose LVEF is ≥50% or 2. A drop in LVEF of ≥5% from baseline in patients whose LVEF decreases to b50%. Baseline LVEF must be measured within 6 weeks of study entry.
Subjects and randomization
Subjects meeting the inclusion/exclusion criteria and giving informed consent are randomized in a 1:1:1 ratio into the 2 treatment and control groups (lisinopril 10 mg a day vs Coreg XR 10 mg vs placebo). The target enrollment is 468 patients at 128 centers. The enrollment is completed. Half of the patients were exposed to ACs prior to TZB therapy, whereas the other half was not. In terms of randomization, once a patient consented to study, the site would call a toll-free number and place the participant eligibility outsources information into the automated system that would simultaneously enroll and randomize the patient to study agent. The site pharmacy would receive and automated email with a bottle number to dispense with the patients assigned blinded study agent. 
Study procedures and follow-up
The study flow is summarized in the Figure. TZB therapy was interrupted when the subjects met the definition of cardiotoxicity. If the patient developed heart failure during the study, TZB was discontinued, study assignment was unblinded, and further care was provided by local cardiologist in accordance with the guidelines. Nevertheless, follow-up visits take place every 3 months, with documentation of the disease status, medical management, LVEF, BNP and TnI, as well as QOL questionnaire at months 6 and 12.
Statistical analyses
The primary aim of this study is to determine if treatment with lisinopril or carvedilol phosphate-ER results in reduction in incidence of TZB-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of LVEF, and comparison of the LVEF of each treatment group with the placebo arm (where LVEF is a continuous variable). The study is stratified according to whether patients received an AC-containing regimen or not to ensure balanced randomization.
The study uses a 2-stage analysis plan. We will first compare each active-agent arm with the placebo arm. If a reduction effect is statistically significant in both agents (ACE and BB), we will examine if there is any difference between the 2 study agents, recognizing we do not have the same statistical power for this secondary analysis. If one or neither of the active agent arms is statistically significantly different from the placebo arm, then the secondary-stage analysis will not be necessary. KaplanMeier survival curves will be constructed to reflect time until event rates, and the log-rank statistic will be used to compare them. Secondary end points will be addressed by using a Student t test to compare the changes of LVEF as a continuous measure between the 2 arms (treatment arms with placebo), and a Pearson χ 2 test will be used to compare the proportions of decreased LVEF in each arm. For comparisons of each treatment with placebo, we will consider 1-sided .025 significant levels to adjust for the multiple testing. A mixed linear model will be used to analyze the pattern of LVEF change during the course of this study using the data from all follow-up visits. Furthermore, a proportional-hazards model will be used to control for potential confounders such as use of other cardiotoxic agents (ie, AC). QOL changes will be evaluated using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire-C30 V 3.0 at baseline and at the end of treatment (end of TZB therapy or week 52). The analysis plan will use a linear regression model to consider the treatment effects on these measurements (dependent variables) adjusted for age and other covariates to compare the treatment arms. The observed data will be evaluated for normality, and appropriate transformation will be introduced prior to conducting the analysis. To assess the long-term effect of the study agents, follow-up measurements will be collected at study months 18 and 24 (or 6 and 12 months after the last dose of TZB, if it was discontinued before week 52). This exploratory analysis will be completed to determine the long-term effects on the prevention of cardiomyopathy and impact on QOL for either or both study agents. The treatment groups will be compared using appropriate 2-sample tests.
Sample size. The sample size calculation is based on the comparisons of each treatment with placebo. Using a conservative incidence estimate, we hypothesize that 15% of women treated for breast cancer with adjuvant TZB will have decreased LVEF in the placebo arm as compared with 5% of the women on the treatment arms. To detect a 10% difference in women who exhibit a decrease in LVEF by the additional medication of lisinopril or carvedilol, a sample size of 141 participants per arm is required to achieve 80% power for a 1-sided test at the .025 significance level. Assuming a 10% dropout rate, 468 subjects were randomized to 1 of the 3 arms.
If possible, all statistical analyses will be based on the intent-to-treat principle. Subjects will be analyzed according to their randomized assignment.
Biomarkers: BNP and troponin
BNP and troponin are the biomarkers being checked regularly while participating on study. The will be used in an effort to identify patients at risk for cardiomyopathy before they develop symptoms and before the drop of LVEF can be appreciated by echocardiography or multigated acquisition scan (MUGA). Cardiac TnI may be a very reliable biomarker. In a single-center study by Cardinale et al, 7 only 5% of patients without TnI elevation in the course of treatment developed cardiomyopathy. On the other hand, 62% of those with elevated TnI later had reduced EF. Moreover, there was less recovery of cardiac function in those patients who had elevated TnI. If this is confirmed in a randomized clinical trial like the one we are doing now, the strategy may be changed from imaging patients every 3 months which is cumbersome and costly to screening them with TnI first and selectively imaging only those in whom it is abnormal. There are no data on head-to-head comparison on BNP and TnI. Receiver operating characteristic (ROC) curves will be used to determine the value of these biomarkers in predicting TZB-induced cardiotoxicity: The null hypothesis is that areas under ROC for the 2 biomarkers regarding identification of TZB-induced cardiotoxicity (primary endpoint) are equal. The areas under ROC will be tested using Delong's nonparametric approach, applying generalized U statistics to generate an estimated covariance matrix for correlated ROC curves. Because of the uncertainty about the treatment effect of the active drugs, this analysis will be limited to the placebo group only. With approximately 15% incidence rate in the placebo group, the proposed sample size will achieve a power N80% to reject the null if the true.
Safety management
Patients are monitored for adverse events attributable to study agent at every study visit according to the Common Terminology Criteria for Adverse Events v4.0. All adverse events attributable to study agent were reported to the SunCoast CCOP Research Base staff according to FDA guidelines. The study was also reviewed for safety and progress by a Data Safety Monitoring Board every 6 months.
Discussion
This prospective, randomized, multicenter, doubleblind, placebo-controlled trial is the largest study to address the prevention of TZB-induced cardiotoxicity. Unlike this study, most similar studies addressing this important clinical issue are conducted in single centers, with smaller sample size and less rigorous design. 7, 8 The incidence of cardiomyopathy reported in individual clinical trials varies widely and ranges from 7% 4 to 34%. 11 In an overview of selected clinical trials on adjuvant breast cancer treatment, Ewer and O'Shaughnessy 12 reported that overt clinical heart failure developed in b4% of patients, whereas asymptomatic decline in LVEF by 10 points was seen in ≤30% of patients. Bengala et al report adverse cardiac effects in 5 of 28 (17.9%), with 2 of them (3.8%) symptomatic. 13 Bhimaraj et al 14 report cardiac dysfunction in 32%, including 14.3% symptomatic, in their mixed adjuvant and metastatic patients. The University of Texas M.D. Anderson Cancer Center (Houston, TX) observed cardiomyopathy in 28% of patients, with a more stringent definition of EF decline: ≥20% from the baseline. There was also 1 cardiac-related death (0.5%). 15 Our sample size calculation, based on the anticipated cardiotoxicity rate of 15%, appears to be quite realistic.
In terms of clinical course of cardiac dysfunction which is secondary to TZB, it appears to be mostly reversible. The MD Anderson Cancer center study, in which patients were referred for suspected TZB-related cardiomyopathy, LVEF decreased from 61% ± 13% at baseline to 43% ± 16% (P b .0001) after TZB and increased to 56% ± 11% after the discontinuation of therapy. 16 Improvement in LVEF occurs after discontinuation of TZB, with cardiac medications or without them, and reexposure to TZB usually does not result in further decline in LVEF. 4, 15, 17 However, current protocols mandate discontinuation of TZB after LVEF becomes abnormally low (b50%), and many women with breast cancer experience interruptions in therapy. 6 We designed our trial in an effort to prevent the development of TZB-related cardiac dysfunction, using the medications that were reported to provide some favorable effects, in a randomized, double-blinded, placebo-controlled population. Our ultimate goal is to find the way to protect the heart and to avoid interruptions in the course of TZB.
The trial is designed for community oncology groups rather than large institutions.
While the trial was in progress, results of 2 other randomized trials were published. Although on a smaller scale, the 2 groups of investigators tried to answer similar question.
In the Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research trial, with a double-blinded, placebo-controlled design, patients with HER2-positive breast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1, with 33, 31, and 30 patients, respectively) for the duration of TZB adjuvant therapy. After 17 cycles of TZB, indexed left ventricular end-diastolic volume increased similarly in all patients, but TZB-induced decline in LVEF was attenuated in bisoprolol-treated patients (−1% ± 5%) relative to the perindopril (−3% ± 4%) and placebo (−5% ± 5%) groups (P = .001). Perindopril and bisoprolol use was an independent predictor of maintained LVEF on multivariable analysis. 18 The second trial used angiotensin II antagonist candesartan for prevention of TZB-related cardiotoxicity (defined as a decline in LVEF of N5% or a decrease below the absolute value 45%) in adjuvant setting. With a total of 206 participants, randomized 1:1 into candesartan or placebo, the trial demonstrated no difference in the number of cardiac events between the groups. Moreover, candesartan did not affect changes in NT-proBNP and troponin values. 19 
